EFFICACY OF HMG-CoA REDUCTASE INHIBITORS IN COVID-19 PATIENTS MORTALITY RATE: A META-ANALYSES OF RANDOMIZED CONTROL TRIALS
AIM: This study aims to evaluate the efficacy of HMG-CoA reductase inhibitors in the mortality of patients with Covid-19 BACKGROUND: The sudden emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 sparked a pandemic of coronavirus disease 2019 (COVID-19), leading to...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524004211 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850035755708055552 |
|---|---|
| author | Mohammadreza Shafiei Mohammadamin Keykhah |
| author_facet | Mohammadreza Shafiei Mohammadamin Keykhah |
| author_sort | Mohammadreza Shafiei |
| collection | DOAJ |
| description | AIM: This study aims to evaluate the efficacy of HMG-CoA reductase inhibitors in the mortality of patients with Covid-19 BACKGROUND: The sudden emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 sparked a pandemic of coronavirus disease 2019 (COVID-19), leading to the pressing global health crisis and unprecedented challenges to healthcare systems and scientific communities. The benefit of HMG-CoA reductase inhibitors usage is under debate. METHODS: A comprehensive literature search in Medline, Cochrane, and ClinicalTrial.gov databases was conducted up to May 2024. A systematic review and meta-analysis of included studies were applied using PRISMA guidelines. RESULTS: Our search reached 6 RCTs comprising 2022 patients, including 823 intervention and 1199 placebo groups. Our analysis revealed that statin use slightly reduced the mortality rate (RR 0.95; 95% CI 0.82-1.09; I2 =0%). There was no significant difference in the dosage of the administered statin in the subgroup meta-analysis. CONCLUSIONS: Our study demonstrated that there is no significant difference in the mortality rate between patients receiving HMG-CoA reductase inhibitors and patients with no intervention (placebo-receiving). |
| format | Article |
| id | doaj-art-a09a5f3b9f914f6b9af1fe1590ee46be |
| institution | DOAJ |
| issn | 2213-7165 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj-art-a09a5f3b9f914f6b9af1fe1590ee46be2025-08-20T02:57:24ZengElsevierJournal of Global Antimicrobial Resistance2213-71652024-12-01397510.1016/j.jgar.2024.10.244EFFICACY OF HMG-CoA REDUCTASE INHIBITORS IN COVID-19 PATIENTS MORTALITY RATE: A META-ANALYSES OF RANDOMIZED CONTROL TRIALSMohammadreza Shafiei0Mohammadamin Keykhah1Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, IranStudent Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, IranAIM: This study aims to evaluate the efficacy of HMG-CoA reductase inhibitors in the mortality of patients with Covid-19 BACKGROUND: The sudden emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 sparked a pandemic of coronavirus disease 2019 (COVID-19), leading to the pressing global health crisis and unprecedented challenges to healthcare systems and scientific communities. The benefit of HMG-CoA reductase inhibitors usage is under debate. METHODS: A comprehensive literature search in Medline, Cochrane, and ClinicalTrial.gov databases was conducted up to May 2024. A systematic review and meta-analysis of included studies were applied using PRISMA guidelines. RESULTS: Our search reached 6 RCTs comprising 2022 patients, including 823 intervention and 1199 placebo groups. Our analysis revealed that statin use slightly reduced the mortality rate (RR 0.95; 95% CI 0.82-1.09; I2 =0%). There was no significant difference in the dosage of the administered statin in the subgroup meta-analysis. CONCLUSIONS: Our study demonstrated that there is no significant difference in the mortality rate between patients receiving HMG-CoA reductase inhibitors and patients with no intervention (placebo-receiving).http://www.sciencedirect.com/science/article/pii/S2213716524004211COVID-19HMG-CoA REDUCTASE INHIBITORSSTATINSMETA-ANALYSES |
| spellingShingle | Mohammadreza Shafiei Mohammadamin Keykhah EFFICACY OF HMG-CoA REDUCTASE INHIBITORS IN COVID-19 PATIENTS MORTALITY RATE: A META-ANALYSES OF RANDOMIZED CONTROL TRIALS Journal of Global Antimicrobial Resistance COVID-19 HMG-CoA REDUCTASE INHIBITORS STATINS META-ANALYSES |
| title | EFFICACY OF HMG-CoA REDUCTASE INHIBITORS IN COVID-19 PATIENTS MORTALITY RATE: A META-ANALYSES OF RANDOMIZED CONTROL TRIALS |
| title_full | EFFICACY OF HMG-CoA REDUCTASE INHIBITORS IN COVID-19 PATIENTS MORTALITY RATE: A META-ANALYSES OF RANDOMIZED CONTROL TRIALS |
| title_fullStr | EFFICACY OF HMG-CoA REDUCTASE INHIBITORS IN COVID-19 PATIENTS MORTALITY RATE: A META-ANALYSES OF RANDOMIZED CONTROL TRIALS |
| title_full_unstemmed | EFFICACY OF HMG-CoA REDUCTASE INHIBITORS IN COVID-19 PATIENTS MORTALITY RATE: A META-ANALYSES OF RANDOMIZED CONTROL TRIALS |
| title_short | EFFICACY OF HMG-CoA REDUCTASE INHIBITORS IN COVID-19 PATIENTS MORTALITY RATE: A META-ANALYSES OF RANDOMIZED CONTROL TRIALS |
| title_sort | efficacy of hmg coa reductase inhibitors in covid 19 patients mortality rate a meta analyses of randomized control trials |
| topic | COVID-19 HMG-CoA REDUCTASE INHIBITORS STATINS META-ANALYSES |
| url | http://www.sciencedirect.com/science/article/pii/S2213716524004211 |
| work_keys_str_mv | AT mohammadrezashafiei efficacyofhmgcoareductaseinhibitorsincovid19patientsmortalityrateametaanalysesofrandomizedcontroltrials AT mohammadaminkeykhah efficacyofhmgcoareductaseinhibitorsincovid19patientsmortalityrateametaanalysesofrandomizedcontroltrials |